• Completed

NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma

Updated: May 23

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Descartes08

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.


Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma


Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma


Sponsor

Cartesian Therapeutics


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT03448978


Official Title: Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma


First Posted : February 28, 2018


Click here for details on ClinicalTrials.gov

 

autologous anti-BCMA-CAR-mRNA-transfected CD8+ T lymphocytes

autologous anti-BCMA-CAR-mRNA-transfected CD8+ T lymphocytes

anti-BCMA-CAR-mRNA-transfected autologous CD8+ T cells

autologous anti-BCMA-CAR-mRNA-transfected CD8-positive T cells

autologous anti-BCMA-CAR-mRNA-transfected CD8+ T cells

Descartes-08


Cartesian Therapeutics

 

Biological: Descartes-08

Biological: Descartes-08

Drug: Fludarabine

Drug: Cyclophosphamide


Experimental:

Descartes-08 plus fludarabine/cyclophosphamide pretreat

 

Maryland: The Center for Cancer and Blood Disorders

Bethesda, Maryland, United States, 20817


Oklahoma: University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States, 73104


Virginia: Virgina Cancer Specialists

Fairfax, Virginia, United States, 22031

 

Locations


United States, Maryland

United States, Oklahoma

United States, Virginia




Posts Archive